{"entity":{"id":"annika-auranen","kind":"person","name":"Annika Auranen","aka":[],"tldr":"Chief physician who directs Tays Cancer Centre in Tampere and the FICAN Mid regional cancer centre for central Finland.","summary":"Annika Auranen is Director and chief physician of Tays Cancer Centre (Tays Syöpäkeskus) at Tampere University Hospital, and of Sisä-Suomen syöpäkeskus FICAN Mid, the regional cancer centre for central Finland. The centre operates as part of the Wellbeing Services County of Pirkanmaa and Tampere University, combining cancer treatment and research. The centre's contacts page lists her as Director alongside special advisor Merja Helenius.","asOf":"2026-09-10","links":[{"label":"Source: Tays Cancer Centre contacts page naming the Director","url":"https://www.tayscancercentre.fi/contacts/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fican"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["gynecologic-oncology"],"dependsOn":[],"notes":[],"role":"Director and Chief Physician, Tays Cancer Centre","institutionId":"tays-cancer-centre","specialisms":["Oncology","Cancer centre management","Regional cancer networks"],"profiles":[{"label":"Tays Cancer Centre contacts page","url":"https://www.tayscancercentre.fi/contacts/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Auranen+A%5BAuthor%5D"}],"papers":[{"title":"Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma","journal":"Gynecologic Oncology","year":2018,"doi":"10.1016/j.ygyno.2018.02.016"},{"title":"Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts","journal":"BMC Research Notes","year":2020,"doi":"10.1186/s13104-020-05155-6"},{"title":"ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors","journal":"The Journal of Pathology","year":2019,"doi":"10.1002/path.5356"}],"orcid":"0000-0002-9678-4684"},"route":"/people/annika-auranen/","neighbours":{"institution":[{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","route":"/institutions/fican/"},{"id":"tays-cancer-centre","kind":"institution","name":"Tays Cancer Centre, Tampere University Hospital","route":"/institutions/tays-cancer-centre/"}],"journal":[{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/"}]}}